#	Pagina
attuale pagina	/open-h2020/projects/223593/index.html
-1	/open-fp7/projects/109585/index.html
-2	/open-h2020/projects/208616/index.html

Opendata, web and dolomites

ABOPEN

FIRST INSTANT, OFF-THE-LAB AND USER-FRIENDLY BLOOD GROUPING TEST

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ABOPEN project word cloud

Explore the words cloud of the ABOPEN project. It provides you a very rough idea of what is the project "ABOPEN" about.

million international profitable children rhd worldwide turnover electricity tested created jobs kills millions moving setting hemolytic pioneering months accidents military hdnf lab 220 eldon market single biologicals stored prevented figo federation minute similarly women hdfn outside fetus obstretics gynecology generate majority regions trained grouping device roi network accuracy transfusions curhe limitations eradicated blood attacks personal format 2002 risk overcoming instant erase tests hospitals off 2 laboratory performed easily keeping deaths 2025 countries 141 cells urgent 44 sizeable danish 37c newborn sold immune influential distributors eldoncards mother affordability screening red rhesus world 24 pregnancy despite stop babies 15 procedure customers pregnant founding dry company mothers precision abopen disease works

Project "ABOPEN" data sheet

The following table provides information about the project.

Coordinator	ELDON BIOLOGICALS A/S Organization address address: SANDTOFTEN 10 city: GENTOFTE postcode: 2820 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Project website	https://www.eldoncard.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-05-01 to 2019-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ELDON BIOLOGICALS A/S ELDON BIOLOGICALS A/S Organization address address: SANDTOFTEN 10 city: GENTOFTE postcode: 2820 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (GENTOFTE)	coordinator	50˙000.00

Map

Project objective

Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15% of RhD(-) women are at risk, 220 million women in developing countries should be tested, since the majority do not know their RhD factor type. At Eldon Biologicals AS (a Danish company created in 2002), we are a profitable company that has already sold millions of EldonCards (a pioneering off-the-lab dry format grouping test) in more than 44 countries and has built a well-established worldwide network of customers and distributors. We are part of the influential International Federation of Gynecology and Obstretics (FIGO) and founding member of CURhE, an international initiative to stop HDNF. Now, we are moving one step further from EldonCards overcoming its limitations to erase HDNF from developing countries. To do so, we have created ABOPEN, a user-friendly off-the-lab grouping test that can be stored for up to 24 months at 37C and works similarly to pregnancy tests, identifying the RhD factor type in just 1 minute and a single-step procedure. ABOPEN can be performed outside a laboratory setting (does not need electricity) by non-trained personnel, while keeping its affordability (it costs just €4), precision and accuracy. ABOPEN has also a sizeable market in developed countries, as an instant and easy to use device to find out about blood grouping for urgent transfusions (accidents, hospitals, military) or just personal information. By end of 2025, we expect to generate €8 million in turnover (ROI of 2.2), while creating 7 new jobs for the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABOPEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABOPEN" are provided by the European Opendata Portal: CORDIS opendata.